Skip to NavigationSkip to content

Johnson & Johnson

BenevolentAI announces licensing agreement with Janssen

BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, of Johnson & Johnson. BenevolentAI will use their artificial intelligence technology, named the Judgement Augmented Cognition System, to provide their scientists with the tools to analyse vast amounts of scientific data.

Pfizer sets release date for rival to J&J’s blockbuster drug

Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. The drug will be only the second biosimilar available on the market and Pfizer have hopes to take a chunk out of Remicade’s sales of around $5 billion a year. Pfizer’s Inflectra will enter the market at a discount of 15% against Remicade.

AstraZeneca sells off third drug in five days

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside the US. The deal, which will be completed for $330 million, sees Johnson & Johnson affiliate Cilag GmbH International gain the rights to sell the nasal spray outside of the US.

Patients' insulin pumps are revealed to be hackable by J&J

Johnson & Johnson have begun warning patients that their insulin pumps, that patients attach to their bodies and are controlled by wireless remote control, could potentially be hacked by enterprising hackers. It leaves open the possibility that the devices could be exploited to intentionally overdose diabetics with insulin.

J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial

Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque psoriasis than a placebo or AbbVie’s blockbuster drug, Humira. The data comes from a Phase III trial where 73 percent of patients who received the drug experienced near complete clearance compared with 2.9 of those who received a placebo and compared with Humira’s results of close to 50%. Statistically, the drug is far ahead of Humira.

Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as the ROCKET AF trial, that the blood testing device used to test an anti-clotting drug was not working correctly. The trial was for the blockbuster drug Xarelto (rivaroxaban), which was pitted in the trial against warfarin.

Johnson & Johnson’s Stelara receives FDA approval

The drug is approved for use to treat the skin condition scaly plaque psoriasis and a type of arthritis associated with psoriasis. Crohn's disease is a chronic inflammatory condition in the gastrointestinal tract, causing abdominal pain, diarrhoea, rectal bleeding, weight loss and fever. It affects about 700,000 Americans and nearly 250,000 Europeans, according to Johnson & Johnson.

J&J in $4.33bn eye surgery unit acquisition

Johnson & Johnson has agreed to buy Abbott Laboratories’ eye surgery equipment unit in an all-cash deal for £4.33 billion as part of its strategy to boost its three core businesses.

GSK and J&J file rheumatoid arthritis treatment sirukumab in EU

GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in Europe in an attempt to compete with Roche’s $1.5 billion Actemra.

Sirukumab is an anti-interleukin (IL)-6 monoclonal antibody that selectively binds with high affinity to the IL-6 cytokine, a naturally occurring protein that plays a role in autoimmune conditions, and is designed to interrupt the autoimmune process in RA.

Janssen’s New Drug Application for drug to treat intestinal worms gets US FDA priority review

Johnson & Johnson (NYSE: JNJ) said the US Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for its drug to treat intestinal worm infestations. 

The company said the 500mg chewable mebendazole tablet will provide a treatment and prevention alternative for soil-transmitted helminthiasis (STH). 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches